Long-term Follow-up Gene Therapy Study for RPGR- XLRP

Plain-language summary

This study provided long-term follow-up for patients who had previously received a gene therapy called AAV5-hRKp.RPGR for RPGR-related X-linked retinitis pigmentosa. To take part, patients had to have received this gene therapy in the earlier MGT009 study. It was conducted as a non-phase follow-up study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Janssen Research & Development, LLC

Intervention

AAV5-hRKp.RPGR

Start date

7/31/2017

Estimated completion

9/17/2025

Countries

United States, United Kingdom

Related genes

Locations

• Boston, United States
• Ann Arbor, United States
• Pittsburgh, United States
• Leeds, United Kingdom
• London, United Kingdom

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Received AAV5-hRKp.RPGR in the MGT009 Study

Exclusion Criteria:

* Unwilling or unable to meet with the requirements of the study